Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy by Brugts Jasper J, Danser A H Jan, de Maat Moniek P M, den Uil Corstiaan A, Boersma Eric, Ferrari Roberto, Simoons Maarten L in Current opinion in cardiology (2008).

[PMID: 18520711] PubMed


Several trials demonstrated that angiotensin-converting enzyme inhibitors reduce the incidence of cardiovascular events during long-term follow-up in high-risk and low-risk patients. Clinical treatment guidelines propose that angiotensin-converting enzyme inhibitors should be considered in the routine secondary prevention in the broad group of coronary artery disease patients. This review discusses several approaches to guide angiotensin-converting enzyme-inhibition therapy to more specific groups of patients that are most likely to benefit.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.